<DOC>
	<DOC>NCT00451321</DOC>
	<brief_summary>The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against standard safety and efficacy parameters.</brief_summary>
	<brief_title>TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Adults 12 to 45 years old who are in good general health Confirmed diagnosis of insulin requiring type 1 diabetes mellitus with good glycemic control Measurable Cpeptide levels Females must not be pregnant or lactating and willing to practice contraception No prior malignancy, other than nonmelanoma skin cancer Body Mass Index (BMI) &gt; 32 at screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>type 1 diabetes mellitus</keyword>
	<keyword>diabetes mellitus type 1</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>diabetes</keyword>
</DOC>